PDL BioPharma

Latest Headlines

Latest Headlines

Ariad sells off a share of Iclusig for a shot at $200M in R&D cash

Ariad Pharmaceuticals has inked a deal with PDL BioPharma, trading a long-term royalty on its only marketed drug in exchange for money to develop another.

PDL, Roche duke it out over royalties for Avastin, Herceptin

Even friends have disputes over money sometimes. That's what's happening with PDL BioPharma and Roche's Genentech: PDL wants to take Genentech to arbitration for underpaying royalties, the AP reports.

Most profitable drugmaker? Not a Big Pharma

Which pharma is the most profitable? You might be surprised. A new analysis of net margins by EvaluatePharma tagged companies for profitability, and the winner wasn't one of the biggies. Not Pfizer,

Facet boots vp of business, staff

Just three weeks out of the gate, Redwood City, CA-based Facet Biotech has announced a new restructuring plan. The PDL BioPharma spin-off says it has completed its strategic business review and it

PDL spins off biotech biz

PDL BioPharma has spun off its biotech business into Facet Biotech Corp. Facet will be based in PDL's Redwood City, CA offices while the rest of the company moves to Incline Village, NV. Facet was

BMS inks $710M development deal with PDL

Bristol-Myers Squibb is paying $30 million upfront in a licensing deal for PDL BioPharma's experimental blood cancer vaccine elotuzumab. And will it pay up to $680 million more if the Phase I cancer

Bristol-Myers buys experimental drug rights

The folks at Bristol-Myers Squibb have apparently been shopping: the company will buy the rights

PDL spins off biotech biz

After struggling for months to sell the company or some of its assets, PDL BioPharma has announced plans to spin off its biotech operations into a publicly-traded company. The new company will be

ALSO NOTED: PDL offers bonuses to top execs; Radius earns $28.3M for milestone;Cytokinetics surges on positive data; and much m

> PDL BioPharma says it will pay four top executives nearly $1 million in bonuses through the end of next year to keep them on board as the company undergoes a transformation into an antibody

PDL BioPharma puts out 'for sale' sign

The troubled PDL BioPharma has put out the 'for sale' sign in an attempt to find a buyer for the company as a whole or of its key assets. This comes in addition to an earlier announcement that PDL